Abstract
SUMMARYNucleoside analogues are widely used in clinical practice as chemotherapy drugs. Arabinose nucleoside derivatives such as Fludarabine are effective in the treatment of patients with acute and chronic leukemias and non-Hodgkin lymphomas. Although nucleoside analogues are generally known to function by inhibiting DNA synthesis in rapidly proliferating cells, the identity of theirin vivotargets and mechanism of action are often not known in molecular detail. Here we provide a structural basis for inhibition by arabinose nucleotides of human primase, the DNA-dependent RNA polymerase responsible for initiation of DNA synthesis in DNA replication. Our data suggest ways in which the chemical structure of Fludarabine could be modified to improve its specificity and affinity towards primase, possibly leading to less toxic and more effective therapeutic agents.
Publisher
Cold Spring Harbor Laboratory
Reference53 articles.
1. PHENIX: a comprehensive Python-based system for macromolecular structure solution
2. Mechanism of Concerted RNA-DNA Primer Synthesis by the Human Primosome
3. Inhibition of Primer RNA Formation in CCRF-CEM Leukemia Cells by Fludarabine Triphosphate;Cancer Res,1991
4. Primer RNA Chain Termination Induced by 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5’- Triphosphate;J. Biol. Chem,1993
5. Fludarabine Phosphate: A Synthetic Purine Antimetabolite;J. Clin. Oncol,1991